References
1. Moise Jr. K.J., Argoti P.S. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol, 2012. 120 (5): p. 1132-9.
2. Geaghan S.M. Diagnostic laboratory technologies for the fetus and neonate with isoimmunization. Semin Perinatol, 2011. 35 (3): p. 148-54.
3. Delaney, M., Matthews D.C. Hemolytic disease of the fetus and newborn: managing the mother, fetus, and newborn. Hematology Am Soc Hematol Educ Program, 2015. 2015 : p. 146-51.
4. Murray, N.A., Roberts I.A.G. Haemolytic disease of the newborn. Arch Dis Child Fetal Neonatal Ed, 2007. 92 (2): p. F83-8.
5. Smitherman H., Stark A.R., Bhutani V.K. Early recognition of neonatal hyperbilirubinemia and its emergent management. Semin Fetal Neonatal Med, 2006. 11 (3): p. 214-24.
6. Bhat Y.R., Kumar C.G.P. Morbidity of ABO haemolytic disease in the newborn. Paediatr Int Child Health, 2012. 32 (2): p. 93-6.
7. Kumar R., Saini N., Kaur P., Sood T., Kaur P., Bedi R.K., et al. Severe ABO Hemolytic Disease of Newborn with High Maternal Antibody Titres in a Direct Antiglobulin Test Negative Neonate. Indian J Pediatr, 2016. 83 (7): p. 740-1.
8. Metcalf R.A., Khan J., Andrews J., Mayock D., Billimoria Z., Pagano M.B., et al. Severe ABO Hemolytic Disease of the Newborn Requiring Exchange Transfusion. J Pediatr Hematol Oncol, 2019. 41 (8): p. 632-634.
9. Burgos A.E., Schmitt S.K., Stevenson D.K., Phibbs C.S. Readmission for neonatal jaundice in California, 1991-2000: trends and implications. Pediatrics, 2008. 121 (4): p. e864-9.
10. Maisels M.J., Kring E. Length of stay, jaundice, and hospital readmission. Pediatrics, 1998. 101 (6): p. 995-8.
11. Sgro M., Campbell D., Shah V. Incidence and causes of severe neonatal hyperbilirubinemia in Canada. CMAJ, 2006. 175 (6): p. 587-90.
12. Matteocci A., Rosa A.D., Buffone E., Pierelli L. Retrospective analysis of HDFN due to ABO incompatibility in a single institution over 6 years. Transfus Med, 2019. 29 (3): p. 197-201.
13. Akanmu A.S., Oyedeji O.A., Adeyemo T.A., Ogbenna A.A. Estimating the Risk of ABO Hemolytic Disease of the Newborn in Lagos. J Blood Transfus, 2015. 2015 : p. 560738.
14. Newman T.B., Xiong B., Gonzales V.M., Escobar G.J. Prediction and prevention of extreme neonatal hyperbilirubinemia in a mature health maintenance organization. Arch Pediatr Adolesc Med, 2000.154 (11): p. 1140-7.
15. American Academy of Pediatrics Subcommittee on Hyperbilirubinemia. Management of hyperbilirubinemia in the newborn infant 35 or more weeks of gestation. Pediatrics, 2004. 114 (1): p. 297-316.
16. Han P., Kiruba R., Ong R., Joseph R., Tan K.L., Wong H.B. Haematolytic disease due to ABO incompatibility: incidence and value of screening in an Asian population. Aust Paediatr J, 1988. 24 (1): p. 35-8.
17. Van Rossum H.H., De Kraa N., Thomas M., Holleboom C.A.G., Castel A., Van Rossum A.P. Comparison of the direct antiglobulin test and the eluate technique for diagnosing haemolytic disease of the newborn. Practical Laboratory Medicine, 2015. 3 : p. 17-22.
18. Izetbegovic S. Occurrence of ABO And RhD Incompatibility with Rh Negative Mothers. Mater Sociomed, 2013. 25 (4): p. 255-8.
19. Einarsdottir H., Ji Y., Visser R., Chunyan M., Guangping L., Scherjon S. H435-containing immunoglobulin G3 allotypes are transported efficiently across the human placenta: implications for alloantibody-mediated diseases of the newborn. Transfusion, 2014.54 (3): p. 665-71.
20. Bakkeheim E., Bergerud U., Schmidt-Melbye AC., Akkök C.A., Liestøl K., Fugelseth D. Maternal IgG anti-A and anti-B titres predict outcome in ABO-incompatibility in the neonate. Acta Paediatr, 2009.98 (12): p. 1896-901.
21. Valsami S., Politou M., Boutsikou T., Briana D., Papatesta M., Malamitsi-Puchner A. Importance of Direct Antiglobulin Test (DAT) in Cord Blood: Causes of DAT (+) in a Cohort Study. Pediatr Neonatol, 2015.56 (4): p. 256-60.
22. Kaplan M., Hammerman C., Vreman H.J., Wong R.J., Stevenson D.K. Hemolysis and hyperbilirubinemia in antiglobulin positive, direct ABO blood group heterospecific neonates. J Pediatr, 2010. 157 (5): p. 772-7.
23. Garratty G., Glynn S.A., McEntire R. ABO and Rh(D) phenotype frequencies of different racial/ethnic groups in the United States. Transfusion, 2004. 44 (5): p. 703-6.
24. Bhutani V.K., Johnson L., Sivieri E.M. Predictive ability of a predischarge hour-specific serum bilirubin for subsequent significant hyperbilirubinemia in healthy term and near-term newborns. Pediatrics, 1999. 103 (1): p. 6-14.
25. Christensen R.D., Baer V.L., MacQueen B.C., O’Brien E.A., Ilstrup S.J. ABO hemolytic disease of the fetus and newborn: thirteen years of data after implementing a universal bilirubin screening and management program. J Perinatol, 2018. 38 (5): p. 517-525.